Hinge Health CEO Daniel Perez disposes of $22.3 million in company stock

On September 10, 2026, Hinge Health CEO Daniel Perez and his spouse disposed of approximately $22.3 million worth of company stock. This sale, executed under a Rule 10b5-1 trading plan, occurred as the stock price neared its 52-week high of $95.57, following a 99% increase over the preceding six months. InvestingPro analysis indicates the stock is currently overvalued compared to its fair value and lists it among 14 ProTips available to subscribers, alongside detailed Pro Research Reports for over 1,400 US equities.

Mr. Perez sold 99,000 shares directly, while his spouse sold an additional 150,000 shares indirectly, covering a range of prices from $87.44 to $91.76 per share. Together, they sold a total of 249,000 shares of Class A Common Stock. Additionally, Perez converted 145,000 shares of Class B Common Stock into Class A Common Stock, with an extra 150,000 shares indirectly converted by his spouse. Each Class B share converts to one Class A share at no cost.

In a separate transaction, Perez gifted 45,000 shares of Class A Common Stock. Hinge Health recently reported robust second-quarter results, with earnings per share of $0.59, more than doubling the estimated $0.13. Revenue grew by 53% to $212.8 million, leading the company to raise its 2026 revenue and profit guidance. The firm plans to expand into gastrointestinal health through a $105 million acquisition of Cylinder Health.

Analysts, including Citizens, Stifel, and Truist Securities, have raised their price targets to $107, $115, and $112, respectively, reflecting optimism about the company’s growth trajectory.